Holzer Holzer & Fistel, LLC is investigating whether Ventrus Biosciences, Inc. (“Ventrus” or the “Company”) (NASDAQ: VTUS) and/or certain of its officers complied with the federal securities laws when making statements to investors between December 17, 2010 and June 22, 2012. Specifically, the investigation focuses on a series of statements made during that time regarding the effectiveness of Ventrus’s experimental drug iferanserin, or VEN 309. On June 25, 2012, Ventrus announced that its Phase 3 trial of VEN 309 “failed to demonstrate an improvement in therapy” and that it had “no immediate plans to continue development of VEN 309.” The Company’s stock price fell dramatically on the news.
If you purchased Ventrus common stock between December 17, 2010 and June 22, 2012 and have questions concerning your legal rights, you are encouraged to contact Holzer Holzer & Fistel, LLC and its attorneys Michael I. Fistel Jr., Esq. or Marshall P. Dees, Esq. via email at firstname.lastname@example.org, or email@example.com, or via toll-free telephone at (888) 508-6832.
Holzer Holzer & Fistel, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer Holzer & Fistel, LLC has paid for the dissemination of this promotional communication, and Michael I. Fistel, Jr. is the attorney responsible for its content.Business Wire
Last updated on: 12/02/2013
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.